Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Core Insights - Prelude Therapeutics has appointed Katina Dorton to its Board of Directors, effective October 17, 2025, bringing over 30 years of experience in healthcare and life sciences [1][2] - Ms. Dorton will also take over as Audit Committee Chair, succeeding Mardi C. Dier, who has served on the board since August 2020 [3] - Prelude Therapeutics is focused on advancing its precision oncology drug candidates and aims to create significant shareholder value [2][3] Company Overview - Prelude Therapeutics is a clinical-stage precision oncology company developing innovative medicines for cancer patients with high unmet needs [4] - The company's pipeline includes several novel drug candidates, such as first-in-class SMARCA2 and KAT6A degraders, and it is also researching next-generation degrader antibody conjugates [4] - Prelude's mission is to extend the promise of precision medicine to every cancer patient in need [4]